Jun 03, 2024 8:00 am EDT Mineralys Therapeutics to Participate in the Goldman Sachs 45th Annual Global Healthcare Conference
May 09, 2024 7:00 am EDT Mineralys Therapeutics Reports First Quarter 2024 Financial Results and Provides Corporate Update
May 06, 2024 8:00 am EDT Mineralys Therapeutics to Participate in the Bank of America Securities Health Care Conference
May 02, 2024 8:00 am EDT Mineralys Therapeutics to Announce First Quarter 2024 Financial Results and Host Conference Call on Thursday, May 9, 2024
Mar 21, 2024 7:00 am EDT Mineralys Therapeutics Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Corporate Update
Mar 13, 2024 4:05 pm EDT Mineralys Therapeutics to Announce Fourth Quarter and Full Year 2023 Financial Results and Host Conference Call on Thursday, March 21, 2024
Jan 29, 2024 4:05 pm EST Mineralys Therapeutics to Participate in the Guggenheim Securities 6th Annual Biotechnology Conference
Dec 21, 2023 4:05 pm EST Mineralys Therapeutics Announces First Subject Dosed in Launch-HTN, the Second Pivotal Trial of Lorundrostat for the Treatment of Hypertension
